Multicenter, Randomized, Phase II Trial of Olaparib Plus Radium-223 Versus Radium-223 in Men With Castration-Resistant Prostate Cancer With Bone Metastases (COMRADE).

Journal:

Journal of Clinical Oncology

Published:

2026-05-08

DOI:

10.1200/jco-25-02835

Affiliations:

12

Authors:

22

Go to article

Institutions	Authors	Share
Foundation Medicine, Inc., United States of America (USA)	5.000000	0.23
Dana-Farber Cancer Institute (DFCI), United States of America (USA)	4.000000	0.18
University of California, San Diego (UC San Diego), United States of America (USA)	4.000000	0.18
University of California, Davis (UC Davis), United States of America (USA)	1.000000	0.05
Brigham and Women's Hospital (BWH), United States of America (USA)	1.000000	0.05
Rutgers Cancer Institute of New Jersey (CINJ), United States of America (USA)	1.000000	0.05
NIH National Cancer Institute (NCI), United States of America (USA)	1.000000	0.05
University of Kansas Medical Center (KUMC), United States of America (USA)	1.000000	0.05
The Ohio State University (OSU), United States of America (USA)	1.000000	0.05
University of Pittsburgh Medical Center (UPMC), United States of America (USA)	1.000000	0.05
Marlene and Stewart Greenebaum Comprehensive Cancer Center, United States of America (USA)	1.000000	0.05
University of Wisconsin-Madison (UW-Madison), United States of America (USA)	1.000000	0.05

Interested in Oncology and Carcinogenesis?